Prelude Therapeutics Entered Into A Securities Purchase Agreement With Institutional Investors, To Which The Company Agreed To Issue And Sell Pre-Funded Warrants To Purchase Up To 7,936,759 Shares Of Voting Common Stock At A Price Of $3.1499 Per Warrant

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!